Monte Rosa Therapeutics, Inc. Financials
Monte Rosa Therapeutics, Inc. (GLUE) reported $123.7M in revenue for fiscal year 2025, up 63.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Monte Rosa’s shrinking operating loss reflects better revenue absorption, but cash conversion moved backward as research intensity stayed high.
In the latest year, earnings quality weakened as operating cash flow swung from$42.0M positive to-$22.8M negative. That happened even as the net loss improved to-$38.6M , so reported progress relied more on accounting than on cash creation and forced the balance sheet, not the business itself, to finance a larger share of activity.
Revenue scale is starting to absorb overhead: sales reached
Liquidity improved for a less obvious reason: the current ratio rose to 6.1x even though cash fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Monte Rosa Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Monte Rosa Therapeutics, Inc. has an operating margin of -43.8%, meaning the company loses $44 on every $100 of revenue. This results in a profitability score of 24/100. This is up from -107.3% the prior year.
Monte Rosa Therapeutics, Inc.'s revenue surged 63.5% year-over-year to $123.7M, reflecting rapid business expansion. This strong growth earns a score of 96/100.
Monte Rosa Therapeutics, Inc. has a moderate D/E ratio of 0.93. This balance of debt and equity financing earns a leverage score of 48/100.
With a current ratio of 6.12, Monte Rosa Therapeutics, Inc. holds $6.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 93/100.
Monte Rosa Therapeutics, Inc.'s operations used $22.8M of cash, and capex of $4.7M added to the outflow, for a free cash flow shortfall of $27.5M. This results in a cash flow score of 47/100.
Monte Rosa Therapeutics, Inc. posts a -16.6% return on equity (ROE), meaning it loses $17 for every $100 of shareholders' equity. This results in a returns score of 31/100. This is up from -32.6% the prior year.
Monte Rosa Therapeutics, Inc. scores 2.54, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.2B) relative to total liabilities ($215.6M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Monte Rosa Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Monte Rosa Therapeutics, Inc. reported a net loss of $38.6M while operations used $22.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Monte Rosa Therapeutics, Inc. generated $123.7M in revenue in fiscal year 2025. This represents an increase of 63.5% from the prior year.
Monte Rosa Therapeutics, Inc.'s EBITDA was -$43.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.8% from the prior year.
Monte Rosa Therapeutics, Inc. reported -$38.6M in net income in fiscal year 2025. This represents an increase of 46.9% from the prior year.
Monte Rosa Therapeutics, Inc. earned -$0.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 53.1% from the prior year.
Cash & Balance Sheet
Monte Rosa Therapeutics, Inc. recorded an outflow of $27.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 172.3% from the prior year.
Monte Rosa Therapeutics, Inc. held $129.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Monte Rosa Therapeutics, Inc.'s operating margin was -43.8% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Monte Rosa Therapeutics, Inc.'s net profit margin was -31.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 64.9 percentage points from the prior year.
Monte Rosa Therapeutics, Inc.'s ROE was -16.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 16.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Monte Rosa Therapeutics, Inc. invested $141.5M in research and development in fiscal year 2025. This represents an increase of 16.4% from the prior year.
Monte Rosa Therapeutics, Inc. invested $4.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 17.9% from the prior year.
Not reported for fiscal year 2025.
GLUE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $28.7M | $123.7M+63.5% | $75.6M | $0 | N/A | N/A | N/A |
| R&D Expenses | $170.7M | $141.5M+16.4% | $121.6M+9.2% | $111.3M+30.8% | $85.1M+48.8% | $57.2M+138.1% | $24.0M |
| SG&A Expenses | $39.9M | $36.4M+3.4% | $35.2M+9.8% | $32.0M+17.3% | $27.3M+73.7% | $15.7M+292.7% | $4.0M |
| Operating Income | -$181.9M | -$54.2M+33.2% | -$81.1M+43.4% | -$143.3M-27.5% | -$112.4M-54.2% | -$72.9M-160.2% | -$28.0M |
| Income Tax | -$2.9M | -$1.1M-142.7% | $2.6M+660.4% | $338K | $0 | N/A | N/A |
| Net Income | -$161.1M | -$38.6M+46.9% | -$72.7M+46.3% | -$135.4M-24.7% | -$108.5M-46.7% | -$74.0M-106.1% | -$35.9M |
| EPS (Diluted) | — | -$0.46+53.1% | -$0.98+62.7% | -$2.63-14.3% | -$2.30 | -$2.96 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GLUE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $448.7M+2.3% | $438.7M+44.4% | $303.8M-11.3% | $342.4M-6.5% | $366.3M+641.9% | $49.4M |
| Current Assets | $393.2M+4.2% | $377.4M+59.8% | $236.2M-14.4% | $275.9M-20.9% | $348.7M+699.9% | $43.6M |
| Cash & Equivalents | $129.9M-42.1% | $224.3M+75.1% | $128.1M+133.3% | $54.9M-84.1% | $346.1M+729.9% | $41.7M |
| Total Liabilities | $215.6M-0.1% | $215.8M+73.3% | $124.5M+75.4% | $71.0M+277.3% | $18.8M-80.8% | $98.1M |
| Current Liabilities | $64.2M-59.1% | $156.9M+236.9% | $46.6M+82.2% | $25.6M+53.7% | $16.6M-43.2% | $29.3M |
| Total Equity | $233.1M+4.5% | $222.9M+24.4% | $179.3M-34.0% | $271.4M-21.9% | $347.5M+813.2% | -$48.7M |
| Retained Earnings | -$477.2M-8.8% | -$438.6M-19.9% | -$365.9M-58.7% | -$230.5M-88.9% | -$122.0M-153.8% | -$48.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GLUE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$24.1M | -$22.8M-154.3% | $42.0M+195.9% | -$43.8M+52.6% | -$92.5M-55.8% | -$59.4M-157.5% | -$23.1M |
| Capital Expenditures | $8.0M | $4.7M+17.9% | $4.0M-79.1% | $19.0M+47.5% | $12.9M+32.7% | $9.7M+187.2% | $3.4M |
| Free Cash Flow | -$32.1M | -$27.5M-172.3% | $38.0M+160.5% | -$62.8M+40.4% | -$105.4M-52.5% | -$69.1M-161.3% | -$26.4M |
| Investing Cash Flow | -$316.8M | -$101.8M-129.1% | -$44.5M-150.1% | $88.8M+140.5% | -$219.2M-2171.0% | -$9.7M-184.8% | -$3.4M |
| Financing Cash Flow | $361.5M | $30.4M-69.3% | $98.9M+259.7% | $27.5M+34.3% | $20.5M-94.6% | $377.6M+528.6% | $60.1M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GLUE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | -43.8% | -107.3% | N/A | N/A | N/A | N/A |
| Net Margin | -31.2%+64.9pp | -96.1% | N/A | N/A | N/A | N/A |
| Return on Equity | -16.6%+16.1pp | -32.6%+42.9pp | -75.5%-35.5pp | -40.0%-18.7pp | -21.3% | N/A |
| Return on Assets | -8.6%+8.0pp | -16.6%+28.0pp | -44.6%-12.9pp | -31.7%-11.5pp | -20.2%+52.5pp | -72.7% |
| Current Ratio | 6.12+3.7x | 2.40-2.7x | 5.07-5.7x | 10.79-10.2x | 20.96+19.5x | 1.49 |
| Debt-to-Equity | 0.930.0x | 0.97+0.3x | 0.69+0.4x | 0.26+0.2x | 0.05 | N/A |
| FCF Margin | -22.2%-72.5pp | 50.3% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin.
Similar Companies
Where Monte Rosa Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Monte Rosa Therapeutics, Inc.'s annual revenue?
Monte Rosa Therapeutics, Inc. (GLUE) reported $123.7M in total revenue for fiscal year 2025. This represents a 63.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Monte Rosa Therapeutics, Inc.'s revenue growing?
Monte Rosa Therapeutics, Inc. (GLUE) revenue grew by 63.5% year-over-year, from $75.6M to $123.7M in fiscal year 2025.
Is Monte Rosa Therapeutics, Inc. profitable?
No, Monte Rosa Therapeutics, Inc. (GLUE) reported a net income of -$38.6M in fiscal year 2025, with a net profit margin of -31.2%.
What is Monte Rosa Therapeutics, Inc.'s EBITDA?
Monte Rosa Therapeutics, Inc. (GLUE) had EBITDA of -$43.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Monte Rosa Therapeutics, Inc.'s operating margin?
Monte Rosa Therapeutics, Inc. (GLUE) had an operating margin of -43.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Monte Rosa Therapeutics, Inc.'s net profit margin?
Monte Rosa Therapeutics, Inc. (GLUE) had a net profit margin of -31.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Monte Rosa Therapeutics, Inc.'s return on equity (ROE)?
Monte Rosa Therapeutics, Inc. (GLUE) has a return on equity of -16.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) recorded an outflow of $27.5M in free cash flow during fiscal year 2025. This represents a -172.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Monte Rosa Therapeutics, Inc.'s operating cash flow?
Monte Rosa Therapeutics, Inc. (GLUE) recorded an outflow of $22.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Monte Rosa Therapeutics, Inc.'s total assets?
Monte Rosa Therapeutics, Inc. (GLUE) had $448.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Monte Rosa Therapeutics, Inc.'s capital expenditures?
Monte Rosa Therapeutics, Inc. (GLUE) invested $4.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Monte Rosa Therapeutics, Inc. spend on research and development?
Monte Rosa Therapeutics, Inc. (GLUE) invested $141.5M in research and development during fiscal year 2025.
What is Monte Rosa Therapeutics, Inc.'s current ratio?
Monte Rosa Therapeutics, Inc. (GLUE) had a current ratio of 6.12 as of fiscal year 2025, which is generally considered healthy.
What is Monte Rosa Therapeutics, Inc.'s debt-to-equity ratio?
Monte Rosa Therapeutics, Inc. (GLUE) had a debt-to-equity ratio of 0.93 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Monte Rosa Therapeutics, Inc.'s return on assets (ROA)?
Monte Rosa Therapeutics, Inc. (GLUE) had a return on assets of -8.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Monte Rosa Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Monte Rosa Therapeutics, Inc. (GLUE) had $129.9M in cash against an annual operating cash burn of $22.8M. This gives an estimated cash runway of approximately 68 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Monte Rosa Therapeutics, Inc.'s Altman Z-Score?
Monte Rosa Therapeutics, Inc. (GLUE) has an Altman Z-Score of 2.54, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Monte Rosa Therapeutics, Inc.'s Piotroski F-Score?
Monte Rosa Therapeutics, Inc. (GLUE) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Monte Rosa Therapeutics, Inc.'s earnings high quality?
Monte Rosa Therapeutics, Inc. (GLUE) reported a net loss of $38.6M while operations used $22.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics, Inc. (GLUE) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.